UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults

University Hospitals Cleveland Medical Center.
Posted at 12:47 PM, Nov 05, 2020
and last updated 2020-11-05 12:47:03-05

CLEVELAND — University Hospitals announced Thursday its participation in a novel clinical trial testing multiple therapeutics to treat COVID-19 in adults who don’t require hospitalization.

University Hospitals said it is adding the ACTIV-2 Trial to its arsenal of investigational treatments. ACTIV-2 is a randomized, blinded, controlled study that tests a variety of new agents against placebo.

“This study aims to identify a treatment that can prevent people with COVID-19 from developing advanced disease that requires hospitalization,” said Grace McComsey, MD, Vice President of Research and Associate Chief Scientific Officer at UH in a news release. “UH is at the forefront of testing experimental treatments for COVID-19, including remdesivir, stem cell therapy and convalescent plasma. Patients suffering from complications of COVID-19 have hope at UH thanks to these options.”

This study is one of the few outpatient clinical trials in the Greater Cleveland Area.

“There is significant concern nationally as to how hospitals will handle the burden of both influenza and COVID-19 this winter,” said Mukesh K. Jain, MD, Chief Academic Officer at UH. “Studies focused on helping people recover from COVID-19 at home, without needing hospitalization, are vitally important and we hope our engagement in the ACTIV-2 trial will help us achieve this goal for our community.”

The first investigational agent to be evaluated by ACTIV-2 is an experimental monoclonal antibody treatment called LY-CoV555. This antibody was first identified by a blood sample taken from a patient in the U.S. who recovered from COVID-19.

One’s body produces antibodies to fight infections. Monoclonal antibodies are produced in a lab. LY-CoV555 is given as an infusion into a vein in the arm.

To qualify for the study, participants must have tested positive for SARS-CoV-2 infection in the outpatient setting within seven days and started experiencing symptoms within 10 days of enrolling into a study.

For information about enrolling in the trial at University Hospitals:

Call: 1-833-78-TRIAL

Additional Coronavirus information and resources:

See complete coverage on our Coronavirus Continuing Coverage page.

Rebound Northeast Ohio News 5's initiative to help people through the financial impact of the coronavirus by offering one place to go for information on everything available to help and how to access it. We're providing resources on:

Getting Back to Work - Learn about the latest job openings, how to file for benefits and succeed in the job market.

Making Ends Meet - Find help on topics from rent to food to new belt-tightening techniques.

Managing the Stress - Feeling isolated or frustrated? Learn ways to connect with people virtually, get counseling or manage your stress.

Doing What's Right - Keep track of the way people are spending your tax dollars and treating your community.

We're Open! Northeast Ohio is place created by News 5 to open us up to new ways of thinking, new ways of gathering and new ways of supporting each other.

Click here for a page with resources including a COVID-19 overview from the CDC, details on cases in Ohio, a timeline of Governor Mike DeWine's orders since the outbreak, coronavirus' impact on Northeast Ohio, and link to more information from the Ohio Department of Health, the Cuyahoga County Board of Health, the CDC and the WHO.

See data visualizations showing the impact of coronavirus in Ohio, including county-by-county maps, charts showing the spread of the disease, and more.

The CDC and the Ohio Department of Health are now recommending the use of cloth face coverings in public to slow the spread of COVID-19.

Read more about the CDC's recommendation here. Here is a step-by-step guide on how to make a face mask from common household materials, without having to know how to sew.

View a global coronavirus tracker with data from Johns Hopkins University.